Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events. The study is currently available on the Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19, is an enveloped RNA virus belonging to the human beta-coronavirus family. Being a respiratory virus, SARS-CoV-2 primarily attacks the upper respiratory tract and subsequently propagates to the lower respiratory tract, causing mild to severe respiratory complications.